임상시험 트래커
추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov
기업
60건 표시 (상위 60건)
- 3상모집 중· Type 2 Diabetes MellitusA Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
리드: 아스트라제네카
- 3상모집 중· ER-Positive HER2-Negative Breast CancerA Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
리드: 아스트라제네카
- 3상모집 중· Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHVSurovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
리드: 아스트라제네카
- 3상모집 중· Chronic Obstructive Pulmonary DiseaseLong-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbations
리드: 아스트라제네카
- 3상모집 중· Metastatic Castration-resistant Prostate CancerAZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
리드: 아스트라제네카
- 3상모집 중· Chronic Rhinosinusitis With Nasal PolypsA Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Treatment With Tezepelumab
리드: 아스트라제네카
- 3상모집 중· Systemic Lupus ErythematosusA Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
리드: 아스트라제네카
- 3상모집 중· Relapsed Refractory Multiple MyelomaA Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
리드: 아스트라제네카
- 3상모집 중· Severe AsthmaPhase 3b Study in Patients With Severe Asthma Treated With Tezepelumab
리드: 아스트라제네카
- 3상모집 중· Epithelial Ovarian CancerAZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
리드: 아스트라제네카
- 3상모집 중· Biliary Tract CancerA Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
리드: 아스트라제네카
- 3상모집 중· Large B-cell LymphomaAZD0486 1L Therapy for Elderly or Unfit Participants With LBCL
리드: 아스트라제네카
- 3상모집 중· Non-small Cell Lung Cancer (NSCLC)Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
리드: 아스트라제네카
- 3상모집 중· Breast CancerA Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
리드: 아스트라제네카
- 3상모집 중· Endometrial CancerStudy of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
협력: 아스트라제네카
- 3상모집 중· Small Cell Lung CarcinomaDurvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.
리드: 아스트라제네카
- 3상모집 중· Small-cell Lung CancerA Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
리드: 암젠 · 협력: 아스트라제네카
- 3상모집 중· Paroxysmal Nocturnal HemoglobinuriaStudy of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis
협력: 아스트라제네카
- 3상모집 중· Primary HyperaldosteronismA Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism
리드: 아스트라제네카
- 3상모집 중· Endometrial CancerPuxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
리드: 아스트라제네카
- 3상모집 중· Cardiovascular DiseaseA Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
리드: 아스트라제네카
- 3상모집 중· Urinary Bladder NeoplasmsPerioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
리드: 아스트라제네카
- 3상모집 중· Hepatocellular CarcinomaPhase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
리드: 아스트라제네카
- 3상모집 중· Eosinophilic Granulomatosis With Polyangiitis (EGPA)A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases
리드: 아스트라제네카
- 3상모집 중· Carcinoma, Non-Small Cell LungA Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
리드: 아스트라제네카
- 3상모집 중· Carcinoma, Non-Small-Cell LungStudy of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
리드: 일라이 릴리 · 협력: 아스트라제네카
- 3상모집 중· Chronic Obstructive Pulmonary Disease (COPD)A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
리드: 아스트라제네카 · 협력: 암젠
- 3상모집 중· Chronic Obstructive Pulmonary Disease (COPD)A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
리드: 아스트라제네카 · 협력: 암젠
- 3상모집 중· Chronic Kidney Disease and HypertensionA Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
리드: 아스트라제네카
- 3상모집 중· HER2-positive Gastric CancerA Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
리드: 아스트라제네카
- 3상모집 중· Non Small Cell Lung CancerA Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
협력: 아스트라제네카
- 3상모집 중· Non-squamous Non-small Cell Lung CancerA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
리드: 아스트라제네카
- 3상모집 중· Biliary Tract CancerPhase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
리드: 아스트라제네카
- 3상모집 중· Untreated Follicular LymphomaA Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
리드: 아스트라제네카
- 3상모집 중· Endometrial CancerRandomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for p53abn Endometrial Cancer
협력: 아스트라제네카
- 3상모집 중· Polymyositis, DermatomyositisA Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
리드: 아스트라제네카
- 3상모집 중· Non-small Cell Lung CancerPhase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
리드: 아스트라제네카
- 3상모집 중· Heart Failure and Impaired Kidney FunctionStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
리드: 아스트라제네카
- 3상모집 중· Systemic Lupus ErythematosusAn Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
리드: 아스트라제네카
- 3상모집 중· COPD (Chronic Obstructive Pulmonary Disease)A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
리드: 아스트라제네카
- 3상모집 중· Advanced CancerA Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
협력: 아스트라제네카
- 3상모집 중· Locally Advanced Head and Neck Squamous Cell CarcinomaA Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
리드: 아스트라제네카
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.